Dos Santos Alexssandra Lima Siqueira, Da Silva Jesse Lopes, De Albuquerque Lucas Zanetti, Neto Antônio Lucas Araújo, Da Silva Cecília Ferreira, Cerva Luana Aguiar Mesquita, Small Isabele Avila, Rodrigues Fabiana Resende, De Macedo Fabiane Carvalho, Marcelino Cicera Pimenta, Batista Paula de Mendonça, Rego Maria Aparecida do Carmo, Borba Maria Amélia Carlos Souto Maior, De Melo Andreia Cristina
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Division of Pathology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Breast Cancer (Dove Med Press). 2025 Apr 15;17:349-358. doi: 10.2147/BCTT.S499373. eCollection 2025.
This study aimed to assess the frequency and prognostic significance of programmed cell death ligand 1 (PD-L1) expression and tumor-infiltrating lymphocyte (TIL) subtypes in advanced triple-negative breast cancer (TNBC).
A database search was conducted to identify women with previously untreated locally recurrent inoperable or metastatic TNBC treated between January 2018 and December 2022. The inclusion criteria required formalin-fixed paraffin-embedded samples aged less than four years. PD-L1 expression was evaluated using the PD-L1 IHC 22C3 pharmDx assay, and the combined positive score (CPS) was calculated. TIL subtypes were assessed using immunohistochemical staining.
The study included 150 patients, with a median age of 51.5 years. The majority of patients were younger than 65 years, postmenopausal, non-white, and had metastatic TNBC. CPS≥10 was observed in 20.9% of cases, mainly in postmenopausal women. No significant differences were found in demographic characteristics and clinicopathological variables across PD-L1 subgroups. Tumors with PD-L1 CPS≥10 had higher expression of CD3+, CD4+, and CD8+ TIL subtypes. Most patients received first-line chemotherapy, with smaller proportions undergoing second, third, and fourth-line treatments. No statistically significant differences were observed in median progression-free survival (PFS) or overall survival (OS) across PD-L1 subgroups in this cohort of chemotherapy-treated patients.
This study provides insights into the expression profiles of PD-L1 and TIL subtypes in advanced TNBC. The PD-L1 CPS status did not significantly affect survival outcomes, but variations in TIL subtype composition were observed based on PD-L1 CPS status.
本研究旨在评估程序性细胞死亡配体1（PD-L1）表达及肿瘤浸润淋巴细胞（TIL）亚型在晚期三阴性乳腺癌（TNBC）中的频率和预后意义。
进行数据库检索，以识别2018年1月至2022年12月期间接受治疗的既往未治疗的局部复发性不可手术或转移性TNBC女性患者。纳入标准要求福尔马林固定石蜡包埋样本的保存时间少于四年。使用PD-L1 IHC 22C3药物诊断检测法评估PD-L1表达，并计算综合阳性评分（CPS）。通过免疫组织化学染色评估TIL亚型。
该研究纳入了150例患者，中位年龄为51.5岁。大多数患者年龄小于65岁，为绝经后女性，非白人，且患有转移性TNBC。20.9%的病例观察到CPS≥10，主要见于绝经后女性。在PD-L1亚组之间，人口统计学特征和临床病理变量未发现显著差异。PD-L1 CPS≥10的肿瘤中CD3 +、CD4 +和CD8 + TIL亚型的表达较高。大多数患者接受一线化疗，接受二线、三线和四线治疗的比例较小。在该化疗治疗患者队列中，各PD-L1亚组的中位无进展生存期（PFS）或总生存期（OS）未观察到统计学显著差异。
本研究深入了解了晚期TNBC中PD-L1和TIL亚型的表达谱。PD-L1 CPS状态并未显著影响生存结果，但基于PD-L1 CPS状态观察到TIL亚型组成存在差异。
